RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

  • RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors.
  • Craig-Hallum’s 22nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series of one-on-one meetings with investors.

A live webcast of the RBC conference presentation will be accessible through Repligen’s  website at , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at , and follow us on .

Repligen Contact:

Jacob Johnson

VP, Investor Relations

(781) 419-0204



EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE

Repligen Announces Publication of the Company’s 2024 Corporate Sustain...

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways...

 PRESS RELEASE

Repligen Corporation to Present at William Blair Growth Conference

Repligen Corporation to Present at William Blair Growth Conference WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen’s  website at , and wil...

Repligen Corp: 1 director

A director at Repligen Corp sold 26,447 shares at 123.707USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Corporation to Present at Upcoming May Investor Conferences WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investo...

 PRESS RELEASE

Repligen Reports First Quarter 2025 Financial Results

Repligen Reports First Quarter 2025 Financial Results Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period en...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch